Company / PP&E (Net)
MoonLake Immunotherapeutics PP&E (Net) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$577.0K
FY2025
5-year range
$45.7K / $722.0K
FY2021-FY2025
Trend
-20.1%
vs FY2024
Sector context
#165 of 193
Health Care
What the data says
MoonLake Immunotherapeutics's pp&e (net) of $577,000 is lower than 85% of companies in the Health Care sector (FY2025). Improved from $320,865 to $577,000 over the past 2 years.
Based on SEC 10-K filings.
$577,000 in FY2025 with a 3-year CAGR of +126.9%.
Improved from $320,865 to $577,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +126.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 193This company $577.0K Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +126.9%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 20.1% year-over-year.
- Ranks #165 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $577.0K | -20.1% |
| FY2024 | $722.0K | +125.0% |
| FY2023 | $320.9K | +549.7% |
| FY2022 | $49.4K | +8.0% |
| FY2021 | $45.7K | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026